CLO Test: What It Is and Why It Matters

The CLO test is a rapid bedside diagnostic tool used during endoscopy to detect Helicobacter pylori, the bacterium responsible for most stomach ulcers and a recognized cause of gastric cancer. Short for “Campylobacter-like organism” test (a name that dates to when the bacterium was first classified), it works by detecting an enzyme called urease that H. pylori produces in abundance. A small tissue sample from the stomach lining is placed into a gel or strip containing urea and a pH indicator; if urease is present, the urea breaks down into ammonia, raising the pH and triggering a visible color change. The test is inexpensive, gives results within hours, and remains one of the most widely used biopsy-based methods for diagnosing this infection.

How the Test Actually Works

H. pylori produces large quantities of urease to survive in the acidic environment of the stomach. The enzyme splits urea into ammonia and carbon dioxide, creating a thin alkaline buffer around the bacterium. The CLO test exploits that same chemistry. When a gastric biopsy specimen is embedded in a gel or pressed onto a strip that contains urea and a pH-sensitive dye, urease from the bacteria breaks down the urea and shifts the surrounding pH upward. That shift turns the indicator from one color to another, typically yellow to pink or red. No urease, no color change. The presence of an antibacterial agent in the test medium helps prevent contamination from other urease-producing organisms that could cause a false alarm.¹

A positive result can appear in as little as a few minutes, but the test is typically read at defined intervals. One study tracking diagnostic performance at multiple time points found that sensitivity started low in the first five minutes (about 40%) but climbed steadily, reaching its highest values after twelve hours, when sensitivity hit roughly 89% and overall accuracy exceeded 90%.² A newer formulation of the CLO test gel was shown to turn positive faster, with a statistically significant edge over the older version at twenty minutes, though the two converged by the three-hour mark. By twenty-four hours, the newer formulation correctly identified all infected patients in that trial, with only a single false positive.³ The practical takeaway is that a quick positive result is reliable, but a negative result at one hour does not necessarily mean the patient is uninfected. Many endoscopy units leave the test running and check it again before discarding it.

Where the Biopsy Is Taken Matters

The stomach is not uniformly colonized by H. pylori. The antrum (the lower portion near the outlet to the small intestine) is the traditional site for CLO test biopsies, and it remains the most commonly sampled area. But a single biopsy from one site can miss infections, especially patchy ones. In one study, a CLO test using one antrum biopsy had a sensitivity of only about 65%, and a single corpus (upper body of the stomach) biopsy performed similarly at roughly 70%. When biopsies from both the antrum and corpus were combined for a single CLO test, sensitivity jumped to about 86% and overall accuracy reached over 95%.⁴

Work from a Nigerian cohort looking at different biopsy locations found that the antrum and the incisura angularis (the sharp curve between the antrum and body) each detected H. pylori at the same rate, around 67%, while the duodenum performed far worse at 17–28%. Adding a second biopsy from the incisura to an antral specimen did not improve detection.⁵ The consensus in gastroenterology practice is that combining one antral and one corpus biopsy gives the best balance between effort and accuracy. This two-site approach is particularly useful when the patient has been on acid-suppressing medications, which tend to push the bacteria away from the antrum toward the corpus.

What Can Make It Wrong

The CLO test’s biggest vulnerability is false negatives, situations where the bacterium is present but the test comes back negative. Several factors drive this problem.

Proton pump inhibitors are the most common culprit. PPIs don’t just reduce acid; they also suppress H. pylori activity and can shift its distribution in the stomach, lowering the concentration of bacteria (and therefore urease) at the biopsy site. One study in patients with bleeding ulcers found that PPI use had a stronger false-negative effect on the CLO test than the presence of blood in the stomach itself.⁶ Another study confirmed that prior PPI and antibiotic consumption induced false-negative results in both the rapid urease test and the urea breath test, while serology and histology were unaffected.⁷ Guidelines generally recommend stopping PPIs at least two weeks before testing, when clinically safe to do so.

Antibiotics create a similar problem. Even a short course taken for an unrelated infection can temporarily reduce bacterial load enough to produce a negative result. Intestinal metaplasia, a condition where stomach lining cells transform into intestinal-type cells, also creates an inhospitable environment for H. pylori and can lead to missed diagnoses.

Active bleeding in the stomach has been a concern, but the evidence is mixed. A prospective study comparing CLO test sensitivity during active upper GI bleeding versus one month later found only a modest difference, with sensitivity of 79% during bleeding and 71% a month afterward. The confidence interval for that difference crossed zero, suggesting the effect of blood alone may be smaller than sometimes assumed.⁸

False positives, on the other hand, are uncommon as long as the test contains an antibacterial agent and is not read after twenty-four hours. Leaving the test out too long allows non-H. pylori bacteria from the sample or the environment to produce urease and trigger a color change that has nothing to do with the infection.¹

How It Stacks Up Against Other Diagnostic Methods

H. pylori can be detected through several techniques, both invasive (requiring endoscopy) and noninvasive. The CLO test competes against histology, culture, the urea breath test, the stool antigen test, and serology. Each has different strengths depending on the clinical scenario.

Histology, where a pathologist examines stained biopsy tissue under a microscope, is often called the gold standard because it can not only find the bacteria but also evaluate the surrounding tissue for inflammation, atrophy, metaplasia, or even malignancy. One institutional comparison found that histology and the rapid urease test agreed in 93% of cases, but histology had greater sensitivity (over 95%) and the added ability to identify other stomach problems.⁹ That said, the CLO test’s advantage is speed and cost: a color change in the endoscopy suite lets the doctor start treatment before the patient even leaves the hospital, while histology results typically take days.

An interesting wrinkle emerged in a study using three separate CLO tests per patient (each with different numbers of biopsies). The CLO test loaded with three biopsies was significantly more sensitive than one with a single biopsy, and it even outperformed histology in that cohort.¹⁰ This reinforces the point that how you use the test, how many biopsies you load and from where, matters as much as which test you pick.

Among noninvasive options, the urea breath test and stool antigen test both perform well. A head-to-head comparison found that the stool antigen test had sensitivity of 96% and specificity of 83%, while the rapid urease test had sensitivity of 93% and specificity of 75%.¹¹ Another study found that histology, the rapid urease test, and the urea breath test all had sensitivity ranging from about 89% to 98%, with specificity above 98% for all three, while serology had high sensitivity but low specificity, making it prone to false positives.¹² Serology detects antibodies that can linger long after the infection has been treated, so it can’t distinguish active from past infection. For that reason, it’s generally not the first choice when you need to confirm whether someone is currently infected.

The bottom line on test selection is usually driven by whether the patient is already getting an endoscopy. If a scope is going in anyway, a CLO test adds minimal time and cost and gives a fast answer. If there’s no clinical reason for endoscopy, a breath test or stool antigen test avoids an invasive procedure altogether.

Different Test Formats

The original CLO test uses an agar gel embedded with urea and a pH indicator. The biopsy specimen is pressed into the gel, and the endoscopist waits for a color change. Several competing products use reagent strips instead, and the practical differences between them can affect accuracy.

One early comparison between the agar-gel CLO test and a reagent-strip product called PyloriTek found that both had the same sensitivity (98%), but the CLO test had markedly better specificity: 92% versus 68% for the strip-based test. The strip produced more false positives, thirteen compared to the CLO test’s three. When PyloriTek results were read within the first hour instead of being left longer, accuracy improved and the false-positive rate dropped significantly.¹³ A separate evaluation found the two formats more comparable at one hour, with an error rate of about 3% for the strip and 5% for the agar gel at that time point.¹⁴ The lesson is that format matters less than timing: strict adherence to recommended reading windows keeps false-positive rates low for both types.

A pediatric multicenter study found that PyloriTek and CLO test results agreed 98% of the time in children, with four cases where the strip was positive but the gel was not.¹⁵ Both formats are considered acceptable for clinical use, and the choice between them typically comes down to institutional preference, cost, and availability.

Using the CLO Test After Treatment

The CLO test is sometimes used not just for initial diagnosis but also to confirm whether eradication therapy has worked. This is where clinicians need to be cautious. A large study examining CLO test accuracy after treatment found that post-therapy sensitivity was only 86%, and it dropped further depending on what therapy the patient had received. Patients who had undergone dual-agent therapy (two antibiotics) had CLO test sensitivity as low as 68–75%, compared with 89–94% after monotherapy. The implication is that more potent antibiotic combinations suppress bacteria enough to fool the test even when the infection isn’t fully cleared.¹⁶ A negative CLO test after treatment, then, should not be treated as definitive proof of eradication. Most guidelines now prefer the urea breath test or stool antigen test for confirming cure, as these can be done noninvasively and are less affected by residual antibiotic activity in the stomach.

The Cost Argument

One reason the CLO test remains so widely used is its cost-effectiveness during endoscopy. A formal economic analysis found that adding biopsy with a rapid urease test to an endoscopy cost about $3,940 per additional symptom-free patient compared with endoscopy alone. More importantly, sending biopsy specimens onward for histology in patients who had a negative rapid urease test provided very little additional benefit and cost over $25,000 per additional cure.¹⁷ For patients already undergoing endoscopy for symptoms like pain, bloating, or reflux, tacking on a CLO test is a cheap addition that can guide treatment within hours.

In settings where endoscopy itself is expensive, noninvasive testing strategies become more attractive. A cost analysis comparing endoscopy-based testing to serology-based testing in children found that total disease management costs were nearly identical in the United States (roughly $643 for endoscopy versus $646 for serology), but in countries where endoscopy is less costly, the endoscopy-based approach was actually cheaper.¹⁸ The economics depend heavily on local pricing, but the CLO test itself is consistently one of the cheapest individual tests in the diagnostic lineup.

Why Detecting H. pylori Matters in the First Place

H. pylori infects roughly half the world’s population, though infection rates vary enormously by geography and socioeconomic conditions. Most carriers never develop symptoms, but the bacterium is the dominant cause of peptic ulcers and chronic gastritis. It is also the only bacterium classified as a definite carcinogen for gastric cancer by the World Health Organization.¹⁹ Eradication with a course of antibiotics and acid suppressors heals ulcers, reduces the risk of recurrence, and in high-risk populations may lower the likelihood of developing gastric cancer. That’s the clinical weight behind an inexpensive color-change test sitting next to the endoscope.

Recovering Live Bacteria from Used CLO Tests

An unusual application of the CLO test goes beyond diagnosis. Researchers have shown that live H. pylori can be recovered from positive CLO test gels and grown in the laboratory, which is useful for antibiotic susceptibility testing. Culture success was about 93% when the positive CLO test was processed within the first hour after endoscopy, but it fell off sharply beyond two hours. Storing the positive test at refrigerator temperature (about 4°C) and plating it within four hours also improved recovery rates.²⁰ This gives endoscopy units a backup option: if they ran a CLO test for a quick diagnosis and later decide they need a culture for drug-resistance testing, the same specimen can serve double duty, as long as it hasn’t been sitting around too long.

The CLO Test in Veterinary Medicine

Humans are not the only species plagued by Helicobacter. Dogs commonly harbor gastric Helicobacter species, though typically not H. pylori itself. A study of dogs with chronic gastrointestinal signs used a combination of rapid urease testing, cytology, histopathology, and PCR. The rapid urease test was positive in about 63% of the dogs, closely matching histopathology, while PCR detected Helicobacter DNA in about 71%. The dominant species were H. heilmannii and H. bizzozeronii, and mixed infections were common. No H. pylori was found in any of the dogs.²¹ The clinical significance of gastric Helicobacter in dogs is still debated. Many healthy dogs carry these organisms without apparent illness, so a positive urease test in a dog doesn’t carry the same treatment implications it does in a human. Still, in veterinary endoscopy suites, the rapid urease test provides the same quick, low-cost answer about whether Helicobacter organisms are present in the stomach.

When to Trust It and When to Ask for More

The CLO test works best as a first-line biopsy-based diagnostic during endoscopy in patients who have not recently taken PPIs or antibiotics. Its specificity is consistently high across studies, meaning a positive result is almost always a true positive. Sensitivity varies widely depending on technique: loading the test with biopsies from two sites pushes it above 85%, while a single-site biopsy can leave it in the mid-60s. Reading the test too early can miss infections that would have shown up with patience.

Situations where the CLO test deserves skepticism include post-treatment confirmation of eradication (where breath and stool tests are preferred), patients on PPIs who cannot safely stop them, and clinical scenarios where identifying tissue changes alongside the infection is important. In those cases, histology adds value that a color change on a gel pad cannot provide. The strength of the CLO test has never been perfection. It’s speed, simplicity, and cost, delivered right there in the procedure room while the patient is still on the table.